USPSTF and ACIP recommendations for screening and prevention.

10 topics · 11 versions · 10 high-yield

← back to all systems

Adult immunization schedule ⭐

adult-immunization-schedule · society: CDC/ACIP · high-yield

2025 ACIP Adult Immunization Schedule (addendum updated July 2, 2025) provides age-based vaccine recommendations for adults ≥19 years in the United States. Schedule is organized by age band (19–26, 27–49, 50–64, ≥65) and is paired with separate tables by medical condition, notes, appendix, and addendum for updated ACIP guidance. Notable 2025 features include the ≥65 recommendation for ≥2 doses of 2024–2025 COVID-19 vaccine, RSV vaccination at age ≥75 (and 50–74 with risk factors), and seasonal RSV in pregnancy.

Aspirin for primary prevention ⭐

aspirin-primary-prevention · society: USPSTF · high-yield

USPSTF 2022 recommendation on low-dose aspirin for primary prevention of cardiovascular disease. For adults 40–59 with ≥10% 10-year CVD risk, initiation is an individual decision (Grade C); for adults ≥60, do not initiate aspirin for primary prevention (Grade D). This replaces the 2016 statement: age range lowered from 50 to 40 for shared decision-making, a new D recommendation added for ≥60, and the prior colorectal cancer benefit claim withdrawn due to inadequate evidence.

Breast cancer screening ⭐

breast-cancer-screening · society: USPSTF · high-yield

The 2024 USPSTF recommends biennial screening mammography for all women aged 40 to 74 years (Grade B), using either digital mammography or digital breast tomosynthesis. This updates the 2016 statement, which had recommended individualized decision-making for women in their 40s; universal screening starting at 40 was driven by rising breast cancer incidence in women 40-49 and modeling showing additional deaths averted, particularly for Black women. Evidence remains insufficient (I statement) for screening women ≥75 years and for supplemental ultrasound or MRI in women with dense breasts.

Cervical cancer screening ⭐

cervical-cancer-screening · society: USPSTF · high-yield

USPSTF cervical cancer screening recommendation for asymptomatic individuals with a cervix. Screen women 21–29 with cytology every 3 years; screen women 30–65 with cytology every 3 years, primary hrHPV testing every 5 years, or hrHPV/cytology cotesting every 5 years (all Grade A). Do not screen women <21, women >65 with adequate prior screening, or women post-hysterectomy with cervix removed and no prior high-grade lesion (Grade D). Major change from 2012: primary hrHPV testing every 5 years added as a stand-alone option for women ≥30.

Colorectal cancer screening ⭐

colorectal-cancer-screening · society: USPSTF · high-yield

USPSTF 2021 recommendations on colorectal cancer screening in average-risk asymptomatic adults. New in this update: screening start age lowered from 50 to 45 years (Grade B for ages 45-49). Screening ages 50-75 remains Grade A; selective screening ages 76-85 remains Grade C; discontinue after 85. Multiple stool-based and direct visualization strategies are endorsed without ranking.

Depression / anxiety screening ⭐

depression-anxiety-screening · society: USPSTF · high-yield

USPSTF 2023 recommends screening all adults ≥19 years, including pregnant/postpartum persons and older adults ≥65, for major depressive disorder (Grade B). Evidence remains insufficient to recommend for or against routine suicide risk screening in asymptomatic adults (I statement). Recommendation is consistent with prior 2016 (depression) and 2014 (suicide) statements; screening must be coupled with systems to ensure diagnosis, treatment, and follow-up.

Lung cancer screening ⭐

lung-cancer-screening · society: USPSTF · high-yield

USPSTF 2021 Grade B recommendation for annual lung cancer screening with low-dose CT (LDCT) in high-risk adults defined by age and smoking history. Compared to the 2013 statement, the age range was expanded (was 55–80, now 50–80 years) and the pack-year threshold was lowered (was 30, now 20 pack-years), nearly doubling the eligible population and partially addressing racial/sex disparities in eligibility. Screening continues annually until 15 years of abstinence, limiting life expectancy, or inability/unwillingness to undergo curative lung surgery.

Prostate cancer screening ⭐

prostate-cancer-screening · society: USPSTF · high-yield

USPSTF 2018 recommendation on PSA-based screening for prostate cancer in asymptomatic men. For men 55-69, screening is an individualized decision after shared decision-making about benefits and harms (Grade C, upgraded from D in 2012 based on longer ERSPC follow-up showing reduced prostate cancer mortality and metastatic disease, plus increased use of active surveillance). For men ≥70 years, routine PSA screening is not recommended (Grade D).

Statins / lipid screening (primary prevention) ⭐

statins-primary-prevention · high-yield

The 2026 ACC/AHA dyslipidemia guideline replaces the 2018 cholesterol guideline and broadens scope to include hypertriglyceridemia and elevated Lp(a). Major changes include adoption of the PREVENT-ASCVD risk equations (replacing the Pooled Cohort Equations) with lower treatment thresholds, reinstatement of explicit LDL-C and non–HDL-C goals, universal once-in-a-lifetime Lp(a) measurement, expanded role for apoB testing, and incorporation of newer agents (bempedoic acid, inclisiran, evinacumab, olezarsen) alongside statins, ezetimibe, and PCSK9 mAbs. The guideline emphasizes the “CPR” framework (Calculate–Personalize–Reclassify with CAC) and earlier intervention to reduce lifetime atherogenic lipoprotein exposure.

Tobacco cessation ⭐

tobacco-cessation · society: USPSTF · high-yield

USPSTF 2021 recommends clinicians ask all adults, including pregnant persons, about tobacco use, advise cessation, and provide interventions (Grade A). Nonpregnant adults should receive both behavioral counseling and FDA-approved pharmacotherapy (NRT, bupropion SR, varenicline); pregnant persons should receive behavioral counseling. Evidence is insufficient (I statement) for pharmacotherapy in pregnancy and for e-cigarettes as a cessation aid in any adult. Recommendations are consistent with the 2015 statement, with new commentary on e-cigarettes and the 2019 EVALI outbreak.

Table of contents